Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates

Core Insights - Aurinia Pharmaceuticals reported quarterly earnings of $0.23 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, and showing an increase from $0.10 per share a year ago, resulting in an earnings surprise of +43.75% [1] - The company achieved revenues of $73.47 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 7.31% and increasing from $67.77 million year-over-year [2] - Aurinia's stock has increased approximately 46.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $70.53 million, while for the current fiscal year, the estimate is $0.62 on revenues of $271.52 million [7] - The estimate revisions trend for Aurinia was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Aurinia belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Xencor, is expected to report a quarterly loss of $0.72 per share, with revenues projected to be $25.66 million, reflecting a year-over-year increase of 139.6% [9]